Trial · NCT02652819
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hb from baseline to the average level | Weeks 7 to 9 inclusive. | Change in Hb from baseline to the average level |
| Secondary | The proportion of subjects who achieve a confirmed Hb response | up to and including Week 9 | The proportion of subjects who achieve a confirmed Hb response |
| Secondary | Proportion of subjects with mean Hb ≥10.0 g/dL | Weeks 7 to 9 | Proportion of subjects with mean Hb ≥10.0 g/dL |
| Secondary | Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged | Weeks 7 to 9 | Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged |
| Secondary | Effect on iron metabolism | Week 9 | Measurement of serum iron |
| Secondary | Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35 | Week 9 | Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35 |
| Secondary | Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50. | Week 9 | Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50. |
| Secondary | Mean change from baseline in mean arterial blood pressure | Weeks 7 to 9 | Mean change from baseline in mean arterial blood pressure |
| Secondary | Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron) | Up to Week 9 | Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron) |
| Secondary | Percent of subjects with treatment-emergent adverse events (TEAEs). | Week 1 up to Week 53 | Percent of subjects with treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) |
| Secondary | Number of subjects with treatment-emergent adverse events (TEAEs). | Week 1 up to Week 53 | Number of subjects with treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) |
| Secondary | Changes from baseline in vital signs | Week 1 up to Week 53 | Measurement of vital signs |
| Secondary | Changes from baseline in ECG findings | Week 1 up to Week 53 | ECG recordings |
| Secondary | Changes from baseline in clinical laboratory values | Week 1 up to Week 53 | Clinical laboratory values |
| Secondary | Proportion of subjects on rescue therapy | Week 1 up to Week 53 | Proportion of subjects on rescue therapy |
| Secondary | Time to rescue therapy from date of first dose | Week 1 up to Week 53 | Time to rescue therapy from date of first dose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02652819/registered